Tau immunotherapy for Alzheimer's disease

Trends in Molecular Medicine

Volumn 21, Issue 6, 2015, Pages 394-402

  Pedersen, Jan Torleif ^a   Sigurdsson, Einar M ^b  

^a H LUNDBECK A S   (Denmark)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Immunotherapy; Tau protein; Tauopathies

Indexed keywords

AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY; TAU PROTEIN; VACCINE; ANTIBODY;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; MICROTUBULE; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN BINDING; REVIEW; AMINO ACID SEQUENCE; ANIMAL; COMPLICATION; IMMUNOLOGY; MOLECULAR GENETICS; PROCEDURES; TAUOPATHIES;

ANIMALIA;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; HUMANS; IMMUNOTHERAPY; MOLECULAR SEQUENCE DATA; TAU PROTEINS; TAUOPATHIES;

EID: 84930538607     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.03.003     Document Type: Review

References (98)

1. World Health Organization and Alzheimer's Disease International Dementia: A Public Health Priority 2012, WHO.
2. Prince M., et al. ADI: World Alzheimer Report 2014, Dementia and Risk Reduction: An Analysis of Protective and Modifiable Factors 2014, ADI, publisher.
3. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
4. Golde T.E. Open questions for Alzheimer's disease immunotherapy. Alzheimers Res. Ther. 2014, 6:3.
5. Weiner M.W., et al. The Alzheimer's Disease Neuroimaging Initiative: review of papers published since its inception. Alzheimers Dement. 2014, 8(1 Suppl.):S1-S68.
6. Breteler M.M., et al. A community-based study of dementia: the Rotterdam Elderly Study. Neuroepidemiology 1992, 11(Suppl. 1):23-28.
7. Launer L.J. Overview of incidence studies of dementia conducted in Europe. Neuroepidemiology 1992, 11(Suppl. 1):2-13.
8. Lambert J.C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 2013, 45:1452-1458.
9. Crary J.F., et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014, 128:755-766.
10. Braak H., Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. 1996, 165(Suppl.):3-12.
11. Nelson P.T., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 2012, 71:362-381.
12. Jack C.R., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
13. Hardy J., Rogaeva E. Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. Exp. Neurol. 2014, 262:75-83.
14. Braak E., et al. Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?. Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249(Suppl. 3):14-22.
15. Clavaguera F., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11:909-913.
16. Frost B., et al. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009, 284:12845-12852.
17. Allen B., et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 2002, 22:9340-9351.
18. Probst A., et al. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. 2000, 99:469-481.
19. Sahara N., et al. Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain. J. Alzheimers Dis. 2013, 33:249-263.
20. Clavaguera F., et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:9535-9540.
21. Ahmed Z., et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 2014, 127:667-683.
22. Walker L.C., et al. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 2013, 70:304-310.
23. Clavaguera F., et al. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 2014, 127:299-301.
24. Goedert M., et al. Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr. Neurol. Neurosci. Rep. 2014, 14:495.
25. Sigurdsson E.M., et al. Infectivity of amyloid diseases. Trends Mol. Med. 2002, 8:411-413.
26. Kolarova M., et al. Structure and pathology of tau protein in Alzheimer disease. Int. J. Alzheimers Dis. 2012, 2012:731526.
27. Hanger D.P., et al. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 2009, 15:112-119.
28. Hasegawa M., et al. Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J. Biol. Chem. 1992, 267:17047-17054.
29. Mandelkow E.M., Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2012, 2:a006247.
30. Mukrasch M.D., et al. Structural polymorphism of 441-residue tau at single residue resolution. PLoS Biol. 2009, 7:e34.
31. Ohgushi M., Wada A. 'Molten-globule state': a compact form of globular proteins with mobile side-chains. FEBS Lett. 1983, 164:21-24.
32. Gamblin T.C., et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10032-10037.
33. deCalignon A., et al. Caspase activation precedes and leads to tangles. Nature 2010, 464:1201-1204.
34. Delobel P., et al. Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am. J. Pathol. 2008, 172:123-131.
35. Griswold-Penner, I. et al. IPerian. Methods of treating tauopathy, US2014294831.
36. Bright J., et al. Human secreted tau increases amyloid-beta production. Neurobiol. Ageing 2015, 36:693-709.
37. Ferreira A., Bigio E.H. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Mol. Med. 2011, 17:676-685.
38. Reinecke J.B., et al. Implicating calpain in tau-mediated toxicity in vivo. PLoS ONE 2011, 6:e23865.
39. Cohen T.J., et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2011, 2:252.
40. Min S.W., et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010, 67:953-966.
41. Zhu Y., et al. The emerging link between O-GlcNAc and Alzheimer's disease. J. Biol. Chem. 2014, 289:34472-34481.
42. Asuni A.A., et al. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007, 27:9115-9129.
43. Boutajangout A., et al. Passive tau immunotherapy deminishes functional decline and clears tau aggregates in a mouse model of tauopathy. Alzheimers Dement. 2010, 6:S578.
44. Boutajangout A., et al. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 2011, 118:658-667.
45. Congdon E.E., et al. Harnessing the immune system for treatment and detection of tau pathology. J. Alzheimers Dis. 2014, 40(Suppl. 1):S113-S121.
46. Theunis C., et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS ONE 2013, 8:e72301.
47. Kontsekova E., et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillar degeneration in an Alzheimer's disease model. Alzheimers Res. Ther. 2014 BC, 6:2-12.
48. Axon Neuroscience SE (2013) : Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease, ClinicalTrials.gov. ctgov:NCT01850238.
49. Pfeifer, A. et al. AC Immune SA. Humanized tau antibody, WO 2013/151762.
50. Pfeifer, A. et al. AC Immune SA. Pharmaceutical composition, WO2012045882.
51. Kontsekova E., et al. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res. Ther. 2014, 6:1-16.
52. Koson P., et al. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Eur. J. Neurosci. 2008, 28:239-246.
53. Feng, C. et al. Panima Pharmaceuticals AG. Human anti-tau antibodies, WO2012049570.
54. Nitsch, R. et al. Human anti-tau antibodies, US2012087861.
55. Yanamandra K., et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013, 80:402-414.
56. Sanders D.W., et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014, 82:1271-1288.
57. Kfoury N., et al. Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 2012, 287:19440-19451.
58. Chai X., et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J. Biol. Chem. 2011, 286:34457-34467.
59. D'Abramo C., et al. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS ONE 2013, 8:e62402.
60. Jicha G.A., et al. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 1997, 48:128-132.
61. Otvos L., et al. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 1994, 39:669-673.
62. Buee L., et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33:95-130.
63. Collin L., et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain 2014, 137:2834-2846.
64. Troquier L., et al. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr. Alzheimer Res. 2012, 9:397-405.
65. Ward S.M., et al. TOC1: characterization of a selective oligomeric tau antibody. J. Alzheimers Dis. 2013, 37:593-602.
66. Patterson K.R., et al. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J. Biol. Chem. 2011, 286:23063-23076.
67. Boutajangout A., et al. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 2010, 30:16559-16566.
68. Congdon E.E., et al. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J. Biol. Chem. 2013, 288:35452-35465.
69. Gu J., et al. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J. Biol. Chem. 2013, 288:33081-33095.
70. Shih H.H., et al. An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition. J. Biol. Chem. 2012, 287:44425-44434.
71. Ittner A., et al. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J. Neurochem. 2015, 132:135-145.
72. Seubert, P. et al. Neotope Biosciences Ltd. Tau immunotherapy, PCT/US2014/025044.
73. Umeda T., et al. Neurodegenerative disorder FTDP-17-related tau intron 10 +16C → T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice. Am. J. Pathol. 2013, 183:211-225.
74. Tomiyama, T. et al. (2014) OC20: passive immunotherapy targeting pSer413-Tau: a pilot study in mice. In Conference Proceedings, Clinical Trials in Alzheimer's Disease (CTAD) 2014, Philadelphia, November 20-23, 2014 (1 edn) pp. 228-229.
75. Umeda T., et al. Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann. Clin. Trans. Neurol. 2015, 2:241-255.
76. Bi M., et al. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS ONE 2011, 6:e26860.
77. Boimel M., et al. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 2010, 224:472-485.
78. Walls K.C., et al. p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci. Lett. 2014, 575:96-100.
79. Castillo-Carranza D.L., et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 2014, 34:4260-4272.
80. Castillo-Carranza D.L., et al. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J. Alzheimers Dis. 2014, 40(Suppl. 1):S97-S111.
81. Nakamura K., et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell 2012, 149:232-244.
82. Nakamura K., et al. Cis phosphorylated tau as the earliest detectable pathogenic conformation in Alzheimer disease, offering novel diagnostic and therapeutic strategies. Prion 2013, 7:117-120.
83. Vincent K.J., Zurini M. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. Biotechnol. J. 2012, 7:1444-1450.
84. Yamada K., et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 2014, 211:387-393.
85. Pooler A.M., et al. A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology 2014, 76:1-8.
86. Krishnamurthy P.K., et al. Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front. Psychiatry 2011, 2:59.
87. Krishnaswamy S., et al. Antibody-derived in vivo imaging of tau pathology. J. Neurosci. 2014, 34:16835-16850.
88. Watkinson R.E., et al. Intracellular antibody immunity. J. Clin. Immunol. 2014, 34(Suppl. 1):S30-S34.
89. Meredith J.E., et al. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. PLoS ONE 2013, 8:e76523.
90. Landen J.W., et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin. Neuropharmacol. 2013, 36:14-23.
91. Yamada K., et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 2011, 31:13110-13117.
92. Cirrito J.R., et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 2003, 23:8844-8853.
93. Chien D.T., et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alzheimers Dis. 2013, 34:457-468.
94. Maruyama M., et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013, 79:1094-1108.
95. Okamura N., et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J. Nucl. Med. 2013, 54:1420-1427.
96. Okamura N., et al. Tau PET imaging in Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 2014, 14:500.
97. Xia C.F., et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013, 9:666-676.
98. Zhang W., et al. A highly selective and specific PET tracer for imaging of tau pathologies. J. Alzheimers Dis. 2012, 31:601-612.